Adrafinil

Elevated heart rate and blood pressure are documented adverse effects of modafinil at clinical doses. While adrafinil/modafinil showed lower cardiovascular stimulant risk than cocaine or bupropion in anaesthetized rats, caution is warranted in patients with pre-existing cardiovascular disease, hypertension, or arrhythmias.

Adrafinil's active metabolite modafinil produces significant DAT occupancy (47–70% at clinical doses) and elevates extracellular dopamine. In patients with a history of psychosis or mania, this dopaminergic stimulation may trigger episodes. No adrafinil-specific psychiatric case reports exist; risk is inferred from modafinil's mechanism of action.

Adrafinil is a prodrug requiring hepatic metabolism to its active form modafinil. In hepatic impairment, conversion is reduced (lowering efficacy), parent compound accumulates (unknown toxicological implications), and modafinil clearance is prolonged. No adrafinil-specific hepatotoxicity data exist, but the additional metabolic burden relative to direct modafinil use raises theoretical concern.

Patients with known hypersensitivity to modafinil or armodafinil must not use adrafinil, as hepatic conversion produces modafinil as the active metabolite. Stevens-Johnson syndrome, erythema multiforme, and DRESS have been reported with modafinil, particularly in pediatric populations.

Pregnancy, Breastfeeding

No human reproductive safety data exist for adrafinil. Standard precaution for stimulant and eugeroic compounds applies. Adrafinil's conversion to modafinil, a dopaminergic and adrenergic agent, poses theoretical risk to fetal and neonatal development.

Modafinil carries FDA warnings regarding serious dermatological reactions in pediatric patients, including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS). These reactions may be accompanied by hepatic involvement. As adrafinil converts to modafinil, the same risk applies.

Modafinil weakly induces CYP3A4/5 (up to 2-fold in vitro), clinically demonstrated to reduce ethinylestradiol and triazolam exposure in healthy volunteers (Robertson et al. 2002). Alternative or backup contraception is required during adrafinil use and for at least one month after cessation.